Leibniz Centre for Tropical Marine Research

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Friday, April 15, 2022
News, Letter, Awareness, Ext, LLP, Central District, NASDAQ, PKU, Food, Court, GLOBE, Company, Program, Patient, Securities Exchange Act of 1934, Person, Lists of diseases, Lists of schools in England, Social media, Pomerantz, Phenix, District court, Complaint, Phenylketonuria, Sailor, Lists of action films, Risk, Leibniz Centre for Tropical Marine Research, SEC Rule 10b-5, Pharmaceutical industry

NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

FIXX CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 11, 2022
Company, Risk, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Fraud, Steve Berman (lawyer), SEC, Program, Person, GLOBE, News, Complaint, SAN, FDA, Social media, Patient, Pharmaceutical industry, Tobacco

SAN FRANCISCO, April 11, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 11, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, LLP, Letter, PKU, Central District, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Complaint, Sailor, Lists of action films, Pomerantz, District court, Phenylketonuria, Program, Court, Lists of schools in England, Food, Lists of diseases, Securities Exchange Act of 1934, Person, GLOBE, News, Ext, Awareness, SEC Rule 10b-5, Social media, Patient, Pharmaceutical industry, Animal

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, April 7, 2022
Company, Risk, Advertising, Letter, Central District, PKU, NASDAQ, NEW, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Investment, District court, Patient, Phenylketonuria, Program, Court, Lists of schools in England, Food, Securities Exchange Act of 1934, GLOBE, Lists of action films, News, Labour government, Awareness, FDA, Social media, The Legal 500, Pharmaceutical industry, Animal, Security (finance)

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.
  • Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

FIXX ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed

Retrieved on: 
Monday, April 4, 2022
Company, Risk, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Fraud, Steve Berman (lawyer), SEC, Program, Person, GLOBE, News, Complaint, SAN, FDA, Social media, Patient, Tobacco, Pharmaceutical industry

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

FIXX ALERT: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit

Retrieved on: 
Saturday, April 2, 2022
Legal, Professional Services, Risk, Letter, PKU, NASDAQ, Private Securities Litigation Reform Act, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Phenylketonuria, Program, Food, Lists of schools in England, SEC, Securities Exchange Act of 1934, Enron, Company, News, CASE, Awareness, Homology, FDA, Lawyer, Social media, History, Tobacco, Pharmaceutical industry

If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .

Key Points: 
  • If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .
  • Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022.
  • THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Homology Medicines securities during the Class Period to seek appointment as lead plaintiff in the Homology Medicines class action lawsuit.
  • A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.

HOMOLOGY MEDICINES, INC. (NASDAQ: FIXX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Homology Medicines, Inc. (NASDAQ: FIXX)

Retrieved on: 
Thursday, March 31, 2022
Company, Risk, Advertising, Letter, Central District, PKU, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, District court, Patient, Phenylketonuria, Program, Court, Lists of schools in England, Food, Securities Exchange Act of 1934, GLOBE, Lists of action films, News, Labour government, Awareness, FDA, Social media, The Legal 500, Pharmaceutical industry, Animal, Security (finance)

On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.

Key Points: 
  • On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • If you purchased FIXX securities, and/or would like to discuss your legal rights and options please visit Homology Medicines, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX

Retrieved on: 
Thursday, March 31, 2022
Company, Risk, LLP, Letter, PKU, Central District, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Complaint, Sailor, Lists of action films, Pomerantz, District court, Phenylketonuria, Program, Court, Lists of schools in England, Food, Lists of diseases, Securities Exchange Act of 1934, Person, GLOBE, News, Ext, Awareness, SEC Rule 10b-5, Social media, Patient, Pharmaceutical industry, Animal

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.

Key Points: 
  • NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Homology Medicines (FIXX) with Significant Losses to Contact Firm, Securities Fraud Class Action Filed

Retrieved on: 
Monday, March 28, 2022
Company, Risk, NASDAQ, Phenix, Leibniz Centre for Tropical Marine Research, Fraud, Steve Berman (lawyer), SEC, Program, Person, GLOBE, News, Complaint, SAN, FDA, Social media, Patient, Tobacco, Pharmaceutical industry

SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and investors with significant losses may have the opportunity to lead the case.
  • Were focused on investors losses and proving Homology lied about HMI-102 data and the therapys commercial prospects, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Homology Medicines and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

ALERT: Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FIXX

Retrieved on: 
Tuesday, March 29, 2022
Legal, Professional Services, Risk, Letter, PKU, NASDAQ, Private Securities Litigation Reform Act, Phenix, Leibniz Centre for Tropical Marine Research, Sailor, Phenylketonuria, Program, Food, Lists of schools in England, SEC, Securities Exchange Act of 1934, Enron, Company, News, CASE, Awareness, Homology, FDA, Lawyer, Social media, History, Pharmaceutical industry, Tobacco

Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points: 
  • Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.
  • If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here .
  • Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022.
  • THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Homology Medicines securities during the Class Period to seek appointment as lead plaintiff in the Homology Medicines class action lawsuit.